Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Trial Profile

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs KSI 301 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors Kodiak Sciences
  • Most Recent Events

    • 21 Dec 2018 According to a Kodiak Sciences media release, the data from this study is expected to be presented at the upcoming ophthalmology Angiogenesis meeting in Miami on 9 Feb 2019.
    • 21 Dec 2018 Results (12 week) presented in a Kodiak Sciences media release.
    • 21 Dec 2018 Status changed from active, no longer recruiting to completed, according to a Kodiak Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top